study_id,outcome,theme,events_x,sample_size_n,country,facility_level,setting,surgical_specialty,denominator_type,ascertainment_window_days,year_start,year_end,pathogen,antibiotic,who_class,ast_method,breakpoint_standard,breakpoint_version,specimen_type,mdr_definition_text,n_mdr,n_xdr,esbl_test,n_esbl_positive,carbapenemase_test,n_carbapenemase_positive,carbapenemase_genes,mrsa_detection_method,resistance_gene_markers,mic_unit,mic_breakpoint_s,mic_breakpoint_r,zone_diameter_unit,ssi_type,readmission_window_days,reoperation_definition_text
Abayneh2022-Ethiopia-MizanTepi-2021-01,amr_prevalence,amr_prevalence,12,12,Ethiopia,tertiary,hospital,,isolates,,2021,2021,Escherichia coli,ampicillin,critically_important,disk_diffusion,CLSI,CLSI 2018,wound_swab,Resistance to three or more classes of antibiotics.,12.0,,,,,,,,,,,,mm,,,
Abayneh2022-Ethiopia-MizanTepi-2021-01,amr_prevalence,amr_prevalence,7,8,Ethiopia,tertiary,hospital,,isolates,,2021,2021,Staphylococcus aureus,ampicillin,critically_important,disk_diffusion,CLSI,CLSI 2018,wound_swab,Resistance to three or more classes of antibiotics.,8.0,,,,,,,cefoxitin disk,,,,,mm,,,
Abayneh2022-Ethiopia-MizanTepi-2021-01,amr_prevalence,amr_prevalence,11,12,Ethiopia,tertiary,hospital,,isolates,,2021,2021,Escherichia coli,amoxicillin-clavulanate,critically_important,disk_diffusion,CLSI,CLSI 2018,wound_swab,Resistance to three or more classes of antibiotics.,12.0,,,,,,,,,,,,mm,,,
Abayneh2022-Ethiopia-MizanTepi-2021-01,amr_prevalence,amr_prevalence,3,8,Ethiopia,tertiary,hospital,,isolates,,2021,2021,Staphylococcus aureus,cefoxitin,critically_important,disk_diffusion,CLSI,CLSI 2018,wound_swab,Resistance to three or more classes of antibiotics.,8.0,,,,,,,cefoxitin disk,,,,,mm,,,
Abosse2021-Ethiopia-FelegeHiwot-2019-01,amr_prevalence,amr_prevalence,27,31,Ethiopia,tertiary,hospital,,isolates,,2019,2019,Staphylococcus aureus,amoxicillin,important,disk_diffusion,CLSI,CLSI 2018,wound_swab,MDR was defined as the ability of an isolate to resist >3 antimicrobial agents in different class.,,,,,,,,,,,,,mm,,,
Abosse2021-Ethiopia-FelegeHiwot-2019-01,amr_prevalence,amr_prevalence,22,31,Ethiopia,tertiary,hospital,,isolates,,2019,2019,Staphylococcus aureus,ampicillin,important,disk_diffusion,CLSI,CLSI 2018,wound_swab,MDR was defined as the ability of an isolate to resist >3 antimicrobial agents in different class.,,,,,,,,,,,,,mm,,,
Abosse2021-Ethiopia-FelegeHiwot-2019-01,amr_prevalence,amr_prevalence,3,31,Ethiopia,tertiary,hospital,,isolates,,2019,2019,Staphylococcus aureus,vancomycin,critically_important,disk_diffusion,CLSI,CLSI 2018,wound_swab,MDR was defined as the ability of an isolate to resist >3 antimicrobial agents in different class.,,,,,,,,,,,,,mm,,,
Abosse2021-Ethiopia-FelegeHiwot-2019-01,amr_prevalence,amr_prevalence,5,31,Ethiopia,tertiary,hospital,,isolates,,2019,2019,Staphylococcus aureus,ciprofloxacin,critically_important,disk_diffusion,CLSI,CLSI 2018,wound_swab,MDR was defined as the ability of an isolate to resist >3 antimicrobial agents in different class.,,,,,,,,,,,,,mm,,,
Abosse2021-Ethiopia-FelegeHiwot-2019-01,amr_prevalence,amr_prevalence,22,26,Ethiopia,tertiary,hospital,,isolates,,2019,2019,Pseudomonas aeruginosa,ampicillin,important,disk_diffusion,CLSI,CLSI 2018,wound_swab,MDR was defined as the ability of an isolate to resist >3 antimicrobial agents in different class.,,,,,,,,,,,,,mm,,,
Abosse2021-Ethiopia-FelegeHiwot-2019-01,amr_prevalence,amr_prevalence,5,26,Ethiopia,tertiary,hospital,,isolates,,2019,2019,Pseudomonas aeruginosa,ciprofloxacin,critically_important,disk_diffusion,CLSI,CLSI 2018,wound_swab,MDR was defined as the ability of an isolate to resist >3 antimicrobial agents in different class.,,,,,,,,,,,,,mm,,,
Abosse2021-Ethiopia-FelegeHiwot-2019-01,amr_prevalence,amr_prevalence,6,26,Ethiopia,tertiary,hospital,,isolates,,2019,2019,Pseudomonas aeruginosa,meropenem,critically_important,disk_diffusion,CLSI,CLSI 2018,wound_swab,MDR was defined as the ability of an isolate to resist >3 antimicrobial agents in different class.,,,,,,,,,,,,,mm,,,
Abosse2021-Ethiopia-FelegeHiwot-2019-01,amr_prevalence,amr_prevalence,14,17,Ethiopia,tertiary,hospital,,isolates,,2019,2019,Klebsiella spp.,ampicillin,important,disk_diffusion,CLSI,CLSI 2018,wound_swab,MDR was defined as the ability of an isolate to resist >3 antimicrobial agents in different class.,,,,,,,,,,,,,mm,,,
Abosse2021-Ethiopia-FelegeHiwot-2019-01,amr_prevalence,amr_prevalence,2,17,Ethiopia,tertiary,hospital,,isolates,,2019,2019,Klebsiella spp.,meropenem,critically_important,disk_diffusion,CLSI,CLSI 2018,wound_swab,MDR was defined as the ability of an isolate to resist >3 antimicrobial agents in different class.,,,,,,,,,,,,,mm,,,
Abosse2021-Ethiopia-FelegeHiwot-2019-01,amr_prevalence,amr_prevalence,2,17,Ethiopia,tertiary,hospital,,isolates,,2019,2019,Klebsiella spp.,gentamicin,critically_important,disk_diffusion,CLSI,CLSI 2018,wound_swab,MDR was defined as the ability of an isolate to resist >3 antimicrobial agents in different class.,,,,,,,,,,,,,mm,,,
Ali2023-Ethiopia-DessieHospital-2016-01,amr_prevalence,amr_prevalence,14,14,Ethiopia,tertiary,hospital,,isolates,,2016,2016,Staphylococcus aureus,penicillin,important,disk_diffusion,CLSI,CLSI M100-S24,wound_swab,ECDC: non-susceptible to at least one agent in three or more antimicrobial categories.,9.0,,,,,,,Cefoxitin (30 μg) disk diffusion; zone diameter ≤21 mm considered resistant,,,,,mm,,,
Ali2023-Ethiopia-DessieHospital-2016-01,amr_prevalence,amr_prevalence,6,14,Ethiopia,tertiary,hospital,,isolates,,2016,2016,Staphylococcus aureus,cefoxitin,important,disk_diffusion,CLSI,CLSI M100-S24,wound_swab,ECDC: non-susceptible to at least one agent in three or more antimicrobial categories.,9.0,,,,,,,Cefoxitin (30 μg) disk diffusion; zone diameter ≤21 mm considered resistant,,,,,mm,,,
Ali2023-Ethiopia-DessieHospital-2016-01,amr_prevalence,amr_prevalence,8,9,Ethiopia,tertiary,hospital,,isolates,,2016,2016,Escherichia coli,ampicillin,important,disk_diffusion,CLSI,CLSI M100-S24,wound_swab,ECDC: non-susceptible to at least one agent in three or more antimicrobial categories.,8.0,,Double disc approximation method,6.0,,,,,,,,,mm,,,
Ali2023-Ethiopia-DessieHospital-2016-01,amr_prevalence,amr_prevalence,7,7,Ethiopia,tertiary,hospital,,isolates,,2016,2016,Klebsiella pneumoniae,ampicillin,important,disk_diffusion,CLSI,CLSI M100-S24,wound_swab,ECDC: non-susceptible to at least one agent in three or more antimicrobial categories.,7.0,,Double disc approximation method,2.0,,,,,,,,,mm,,,
Ali2023-Ethiopia-DessieHospital-2016-01,amr_prevalence,amr_prevalence,21,23,Ethiopia,tertiary,hospital,,isolates,,2016,2016,Enterobacteriaceae,ampicillin,important,disk_diffusion,CLSI,CLSI M100-S24,wound_swab,ECDC: non-susceptible to at least one agent in three or more antimicrobial categories.,,,,,,,,,,,,,mm,,,
Amulioto2020-Kenya-MamaLucyKibaki-2018-2019-1,amr_prevalence,amr_prevalence,2,22,Kenya,tertiary,hospital,,isolates,,2018,2019,Staphylococcus aureus,vancomycin,important,disk_diffusion,CLSI,CLSI 2016,wound_swab,,,,,,,,,Oxacillin disk diffusion,,,,,mm,,,
Amulioto2020-Kenya-MamaLucyKibaki-2018-2019-1,amr_prevalence,amr_prevalence,3,22,Kenya,tertiary,hospital,,isolates,,2018,2019,Staphylococcus aureus,ciprofloxacin,critically_important,disk_diffusion,CLSI,CLSI 2016,wound_swab,,,,,,,,,Oxacillin disk diffusion,,,,,mm,,,
Amulioto2020-Kenya-MamaLucyKibaki-2018-2019-1,amr_prevalence,amr_prevalence,1,22,Kenya,tertiary,hospital,,isolates,,2018,2019,Staphylococcus aureus,chloramphenicol,highly_important,disk_diffusion,CLSI,CLSI 2016,wound_swab,,,,,,,,,Oxacillin disk diffusion,,,,,mm,,,
Amulioto2020-Kenya-MamaLucyKibaki-2018-2019-1,amr_prevalence,amr_prevalence,21,22,Kenya,tertiary,hospital,,isolates,,2018,2019,Staphylococcus aureus,ampicillin,highly_important,disk_diffusion,CLSI,CLSI 2016,wound_swab,,,,,,,,,Oxacillin disk diffusion,,,,,mm,,,
Amulioto2020-Kenya-MamaLucyKibaki-2018-2019-1,amr_prevalence,amr_prevalence,13,22,Kenya,tertiary,hospital,,isolates,,2018,2019,Staphylococcus aureus,oxacillin,highly_important,disk_diffusion,CLSI,CLSI 2016,wound_swab,,,,,,,,,Oxacillin disk diffusion,,,,,mm,,,
Amulioto2020-Kenya-MamaLucyKibaki-2018-2019-1,amr_prevalence,amr_prevalence,7,12,Kenya,tertiary,hospital,,isolates,,2018,2019,Escherichia coli,chloramphenicol,highly_important,disk_diffusion,CLSI,CLSI 2016,wound_swab,Multi-drug resistance (resistance to ≥ 4 antibiotics) observed with E. coli.,,,,,,,,,,,,,mm,,,
Amulioto2020-Kenya-MamaLucyKibaki-2018-2019-1,amr_prevalence,amr_prevalence,11,12,Kenya,tertiary,hospital,,isolates,,2018,2019,Escherichia coli,ampicillin,highly_important,disk_diffusion,CLSI,CLSI 2016,wound_swab,Multi-drug resistance (resistance to ≥ 4 antibiotics) observed with E. coli.,,,,,,,,,,,,,mm,,,
Amulioto2020-Kenya-MamaLucyKibaki-2018-2019-1,amr_prevalence,amr_prevalence,6,11,Kenya,tertiary,hospital,,isolates,,2018,2019,Acinetobacter baumannii,amikacin,critically_important,disk_diffusion,CLSI,CLSI 2016,wound_swab,,,,,,,,,,,,,,mm,,,
Billoro2019-Ethiopia-WUNEMMH-2017-01,amr_prevalence,amr_prevalence,1,9,Ethiopia,tertiary,hospital,,isolates,,2017,2017,Klebsiella pneumoniae,ceftriaxone,critically_important,disk_diffusion,CLSI,,wound_swab,,,,,,,,,,,,,,mm,,,
Billoro2019-Ethiopia-WUNEMMH-2017-01,amr_prevalence,amr_prevalence,1,9,Ethiopia,tertiary,hospital,,isolates,,2017,2017,Klebsiella pneumoniae,ciprofloxacin,critically_important,disk_diffusion,CLSI,,wound_swab,,,,,,,,,,,,,,mm,,,
Billoro2019-Ethiopia-WUNEMMH-2017-01,amr_prevalence,amr_prevalence,3,9,Ethiopia,tertiary,hospital,,isolates,,2017,2017,Klebsiella pneumoniae,gentamicin,critically_important,disk_diffusion,CLSI,,wound_swab,,,,,,,,,,,,,,mm,,,
Billoro2019-Ethiopia-WUNEMMH-2017-01,amr_prevalence,amr_prevalence,2,6,Ethiopia,tertiary,hospital,,isolates,,2017,2017,Klebsiella pneumoniae,chloramphenicol,highly_important,disk_diffusion,CLSI,,wound_swab,,,,,,,,,,,,,,mm,,,
Billoro2019-Ethiopia-WUNEMMH-2017-01,amr_prevalence,amr_prevalence,0,3,Ethiopia,tertiary,hospital,,isolates,,2017,2017,Staphylococcus aureus,ceftriaxone,critically_important,disk_diffusion,CLSI,,wound_swab,,,,,,,,,,,,,,mm,,,
Billoro2019-Ethiopia-WUNEMMH-2017-01,amr_prevalence,amr_prevalence,1,4,Ethiopia,tertiary,hospital,,isolates,,2017,2017,Staphylococcus aureus,ciprofloxacin,critically_important,disk_diffusion,CLSI,,wound_swab,,,,,,,,,,,,,,mm,,,
Boru2025-Ethiopia-BuleHora-2023-01,amr_prevalence,amr_prevalence,1,14,Ethiopia,tertiary,hospital,,isolates,,2023,2023,Staphylococcus aureus,chloramphenicol,highly_important,disk_diffusion,CLSI,,wound_swab,Resistance to ≥3 classes of antimicrobials,8.0,,,,,,,Cefoxitin disk diffusion,,,,,mm,,,
Boru2025-Ethiopia-BuleHora-2023-01,amr_prevalence,amr_prevalence,8,14,Ethiopia,tertiary,hospital,,isolates,,2023,2023,Staphylococcus aureus,cefoxitin,critically_important,disk_diffusion,CLSI,,wound_swab,Resistance to ≥3 classes of antimicrobials,8.0,,,,,,,Cefoxitin disk diffusion,,,,,mm,,,
Boru2025-Ethiopia-BuleHora-2023-01,amr_prevalence,amr_prevalence,8,14,Ethiopia,tertiary,hospital,,isolates,,2023,2023,Staphylococcus aureus,penicillin,critically_important,disk_diffusion,CLSI,,wound_swab,Resistance to ≥3 classes of antimicrobials,8.0,,,,,,,Cefoxitin disk diffusion,,,,,mm,,,
Boru2025-Ethiopia-BuleHora-2023-01,amr_prevalence,amr_prevalence,5,6,Ethiopia,tertiary,hospital,,isolates,,2023,2023,Escherichia coli,ampicillin,critically_important,disk_diffusion,CLSI,,wound_swab,Resistance to ≥3 classes of antimicrobials,3.0,,,,,,,,,,,,mm,,,
Boru2025-Ethiopia-BuleHora-2023-01,amr_prevalence,amr_prevalence,5,6,Ethiopia,tertiary,hospital,,isolates,,2023,2023,Escherichia coli,ceftazidime,critically_important,disk_diffusion,CLSI,,wound_swab,Resistance to ≥3 classes of antimicrobials,3.0,,,,,,,,,,,,mm,,,
Boru2025-Ethiopia-BuleHora-2023-01,amr_prevalence,amr_prevalence,0,6,Ethiopia,tertiary,hospital,,isolates,,2023,2023,Pseudomonas aeruginosa,ciprofloxacin,critically_important,disk_diffusion,CLSI,,wound_swab,Resistance to ≥3 classes of antimicrobials,3.0,,,,,,,,,,,,mm,,,
Burugu2022-Kenya-KenyattaNH-2022-01,amr_prevalence,amr_prevalence,11,12,Kenya,tertiary,hospital,,isolates,,,,Escherichia coli,ceftriaxone,critically_important,disk_diffusion,study_defined,,wound_swab,,,,,,,,,,,,,,mm,,,
Burugu2022-Kenya-KenyattaNH-2022-01,amr_prevalence,amr_prevalence,3,4,Kenya,tertiary,hospital,,isolates,,,,Proteus spp.,ceftriaxone,critically_important,disk_diffusion,study_defined,,wound_swab,,,,,,,,,,,,,,mm,,,
Burugu2022-Kenya-KenyattaNH-2022-01,amr_prevalence,amr_prevalence,9,16,Kenya,tertiary,hospital,,isolates,,,,Staphylococcus aureus,oxacillin,critically_important,disk_diffusion,study_defined,,wound_swab,,,,,,,,,oxacillin disc,,,,,mm,,,
Burugu2022-Kenya-KenyattaNH-2022-01,amr_prevalence,amr_prevalence,3,4,Kenya,tertiary,hospital,,isolates,,,,Enterococcus faecalis,vancomycin,critically_important,disk_diffusion,study_defined,,wound_swab,,,,,,,,,,,,,,mm,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,amr_prevalence,6,10,Kenya,tertiary,hospital,,isolates,,2008,2009,Staphylococcus aureus,ampicillin,important,disk_diffusion,CLSI,2009,pus_swab,,,,,,,,,,,,,,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,amr_prevalence,4,10,Kenya,tertiary,hospital,,isolates,,2008,2009,Staphylococcus aureus,doxycycline,highly_important,,,,,,,,,,,,,,,,,,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,amr_prevalence,3,10,Kenya,tertiary,hospital,,isolates,,2008,2009,Staphylococcus aureus,azithromycin,highly_important,,,,,,,,,,,,,,,,,,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,amr_prevalence,1,10,Kenya,tertiary,hospital,,isolates,,2008,2009,Staphylococcus aureus,amoxicillin-clavulanate,highly_important,,,,,,,,,,,,,,,,,,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,amr_prevalence,1,10,Kenya,tertiary,hospital,,isolates,,2008,2009,Staphylococcus aureus,cefuroxime,highly_important,,,,,,,,,,,,,,,,,,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,amr_prevalence,5,10,Kenya,tertiary,hospital,,isolates,,2008,2009,Staphylococcus aureus,ciprofloxacin,critically_important,,,,,,,,,,,,,,,,,,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,amr_prevalence,2,10,Kenya,tertiary,hospital,,isolates,,2008,2009,Staphylococcus aureus,chloramphenicol,highly_important,,,,,,,,,,,,,,,,,,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,amr_prevalence,1,10,Kenya,tertiary,hospital,,isolates,,2008,2009,Staphylococcus aureus,oxacillin,highly_important,,,,,,,,,,,,,oxacillin_disk_diffusion,,,,,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,amr_prevalence,0,10,Kenya,tertiary,hospital,,isolates,,2008,2009,Staphylococcus aureus,netilmicin,highly_important,,,,,,,,,,,,,,,,,,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,amr_prevalence,0,10,Kenya,tertiary,hospital,,isolates,,2008,2009,Staphylococcus aureus,vancomycin,critically_important,,,,,,,,,,,,,,,,,,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,amr_prevalence,4,5,Kenya,tertiary,hospital,,isolates,,2008,2009,Coagulase-negative staphylococci,ampicillin,important,,,,,,,,,,,,,,,,,,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,amr_prevalence,3,5,Kenya,tertiary,hospital,,isolates,,2008,2009,Coagulase-negative staphylococci,doxycycline,highly_important,,,,,,,,,,,,,,,,,,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,amr_prevalence,3,5,Kenya,tertiary,hospital,,isolates,,2008,2009,Coagulase-negative staphylococci,azithromycin,highly_important,,,,,,,,,,,,,,,,,,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,amr_prevalence,2,5,Kenya,tertiary,hospital,,isolates,,2008,2009,Coagulase-negative staphylococci,amoxicillin-clavulanate,highly_important,,,,,,,,,,,,,,,,,,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,amr_prevalence,3,5,Kenya,tertiary,hospital,,isolates,,2008,2009,Coagulase-negative staphylococci,cefuroxime,highly_important,,,,,,,,,,,,,,,,,,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,amr_prevalence,1,5,Kenya,tertiary,hospital,,isolates,,2008,2009,Coagulase-negative staphylococci,ciprofloxacin,critically_important,,,,,,,,,,,,,,,,,,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,amr_prevalence,2,5,Kenya,tertiary,hospital,,isolates,,2008,2009,Coagulase-negative staphylococci,chloramphenicol,highly_important,,,,,,,,,,,,,,,,,,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,amr_prevalence,0,5,Kenya,tertiary,hospital,,isolates,,2008,2009,Coagulase-negative staphylococci,oxacillin,highly_important,,,,,,,,,,,,,,,,,,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,amr_prevalence,0,5,Kenya,tertiary,hospital,,isolates,,2008,2009,Coagulase-negative staphylococci,netilmicin,highly_important,,,,,,,,,,,,,,,,,,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,amr_prevalence,0,5,Kenya,tertiary,hospital,,isolates,,2008,2009,Coagulase-negative staphylococci,vancomycin,critically_important,,,,,,,,,,,,,,,,,,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,amr_prevalence,0,4,Kenya,tertiary,hospital,,isolates,,2008,2009,Kluyvera spp.,co-trimoxazole,highly_important,,,,,,,,,,,,,,,,,,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,amr_prevalence,3,4,Kenya,tertiary,hospital,,isolates,,2008,2009,Kluyvera spp.,doxycycline,highly_important,,,,,,,,,,,,,,,,,,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,amr_prevalence,2,4,Kenya,tertiary,hospital,,isolates,,2008,2009,Kluyvera spp.,amoxicillin-clavulanate,highly_important,,,,,,,,,,,,,,,,,,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,amr_prevalence,2,4,Kenya,tertiary,hospital,,isolates,,2008,2009,Kluyvera spp.,cefotaxime,critically_important,,,,,,,,,,,,,,,,,,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,amr_prevalence,1,4,Kenya,tertiary,hospital,,isolates,,2008,2009,Kluyvera spp.,chloramphenicol,highly_important,,,,,,,,,,,,,,,,,,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,amr_prevalence,1,4,Kenya,tertiary,hospital,,isolates,,2008,2009,Kluyvera spp.,cefuroxime,highly_important,,,,,,,,,,,,,,,,,,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,amr_prevalence,1,4,Kenya,tertiary,hospital,,isolates,,2008,2009,Kluyvera spp.,ciprofloxacin,critically_important,,,,,,,,,,,,,,,,,,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,amr_prevalence,1,4,Kenya,tertiary,hospital,,isolates,,2008,2009,Kluyvera spp.,gentamicin,highly_important,,,,,,,,,,,,,,,,,,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,amr_prevalence,3,4,Kenya,tertiary,hospital,,isolates,,2008,2009,Escherichia coli,co-trimoxazole,highly_important,,,,,,,,,,,,,,,,,,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,amr_prevalence,3,4,Kenya,tertiary,hospital,,isolates,,2008,2009,Escherichia coli,doxycycline,highly_important,,,,,,,,,,,,,,,,,,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,amr_prevalence,3,4,Kenya,tertiary,hospital,,isolates,,2008,2009,Escherichia coli,amoxicillin-clavulanate,highly_important,,,,,,,,,,,,,,,,,,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,amr_prevalence,1,4,Kenya,tertiary,hospital,,isolates,,2008,2009,Escherichia coli,cefotaxime,critically_important,,,,,,,,,,,,,,,,,,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,amr_prevalence,2,4,Kenya,tertiary,hospital,,isolates,,2008,2009,Escherichia coli,chloramphenicol,highly_important,,,,,,,,,,,,,,,,,,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,amr_prevalence,2,4,Kenya,tertiary,hospital,,isolates,,2008,2009,Escherichia coli,cefuroxime,highly_important,,,,,,,,,,,,,,,,,,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,amr_prevalence,2,4,Kenya,tertiary,hospital,,isolates,,2008,2009,Escherichia coli,ciprofloxacin,critically_important,,,,,,,,,,,,,,,,,,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,amr_prevalence,2,4,Kenya,tertiary,hospital,,isolates,,2008,2009,Escherichia coli,gentamicin,highly_important,,,,,,,,,,,,,,,,,,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,amr_prevalence,2,3,Kenya,tertiary,hospital,,isolates,,2008,2009,Klebsiella spp.,co-trimoxazole,highly_important,,,,,,,,,,,,,,,,,,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,amr_prevalence,1,3,Kenya,tertiary,hospital,,isolates,,2008,2009,Klebsiella spp.,doxycycline,highly_important,,,,,,,,,,,,,,,,,,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,amr_prevalence,2,3,Kenya,tertiary,hospital,,isolates,,2008,2009,Klebsiella spp.,amoxicillin-clavulanate,highly_important,,,,,,,,,,,,,,,,,,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,amr_prevalence,2,3,Kenya,tertiary,hospital,,isolates,,2008,2009,Klebsiella spp.,cefotaxime,critically_important,,,,,,,,,,,,,,,,,,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,amr_prevalence,1,3,Kenya,tertiary,hospital,,isolates,,2008,2009,Klebsiella spp.,chloramphenicol,highly_important,,,,,,,,,,,,,,,,,,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,amr_prevalence,0,3,Kenya,tertiary,hospital,,isolates,,2008,2009,Klebsiella spp.,cefuroxime,highly_important,,,,,,,,,,,,,,,,,,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,amr_prevalence,0,3,Kenya,tertiary,hospital,,isolates,,2008,2009,Klebsiella spp.,ciprofloxacin,critically_important,,,,,,,,,,,,,,,,,,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,amr_prevalence,2,3,Kenya,tertiary,hospital,,isolates,,2008,2009,Klebsiella spp.,gentamicin,highly_important,,,,,,,,,,,,,,,,,,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,amr_prevalence,3,4,Kenya,tertiary,hospital,,isolates,,2008,2009,Pseudomonas aeruginosa,ciprofloxacin,critically_important,,,,,,,,,,,,,,,,,,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,amr_prevalence,2,4,Kenya,tertiary,hospital,,isolates,,2008,2009,Pseudomonas aeruginosa,gentamicin,highly_important,,,,,,,,,,,,,,,,,,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,amr_prevalence,3,4,Kenya,tertiary,hospital,,isolates,,2008,2009,Pseudomonas aeruginosa,piperacillin-tazobactam,critically_important,,,,,,,,,,,,,,,,,,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,amr_prevalence,2,4,Kenya,tertiary,hospital,,isolates,,2008,2009,Pseudomonas aeruginosa,cefepime,critically_important,,,,,,,,,,,,,,,,,,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,amr_prevalence,2,4,Kenya,tertiary,hospital,,isolates,,2008,2009,Pseudomonas aeruginosa,ceftazidime,critically_important,,,,,,,,,,,,,,,,,,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,amr_prevalence,2,4,Kenya,tertiary,hospital,,isolates,,2008,2009,Pseudomonas aeruginosa,imipenem,critically_important,,,,,,,,,,,,,,,,,,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,amr_prevalence,2,4,Kenya,tertiary,hospital,,isolates,,2008,2009,Pseudomonas aeruginosa,piperacillin,highly_important,,,,,,,,,,,,,,,,,,,,,
Dinda2013-Kenya-AKUHNairobi-20082009-1,amr_prevalence,amr_prevalence,1,4,Kenya,tertiary,hospital,,isolates,,2008,2009,Pseudomonas aeruginosa,ceftriaxone,critically_important,,,,,,,,,,,,,,,,,,,,,
Garoy2021-Eritrea-AsmaraHospitals-2017-01,amr_prevalence,amr_prevalence,20,20,Eritrea,tertiary,hospital,,isolates,,2017,2017,Staphylococcus aureus,penicillin,important,disk_diffusion,CLSI,CLSI 2017 (M100-S25),wound_swab,MDR: nonsusceptibility to at least one agent in ≥3 antimicrobial drug classes.,17.0,,,,,,,disk diffusion (oxacillin disk),,,,,mm,,,
Garoy2021-Eritrea-AsmaraHospitals-2017-01,amr_prevalence,amr_prevalence,14,20,Eritrea,tertiary,hospital,,isolates,,2017,2017,Staphylococcus aureus,oxacillin,important,disk_diffusion,CLSI,CLSI 2017 (M100-S25),wound_swab,MDR: nonsusceptibility to at least one agent in ≥3 antimicrobial drug classes.,17.0,,,,,,,disk diffusion (oxacillin disk),,,,,mm,,,
Garoy2021-Eritrea-AsmaraHospitals-2017-01,amr_prevalence,amr_prevalence,12,20,Eritrea,tertiary,hospital,,isolates,,2017,2017,Staphylococcus aureus,vancomycin,critically_important,disk_diffusion,CLSI,CLSI 2017 (M100-S25),wound_swab,MDR: nonsusceptibility to at least one agent in ≥3 antimicrobial drug classes.,17.0,,,,,,,disk diffusion (oxacillin disk),,,,,mm,,,
Garoy2021-Eritrea-AsmaraHospitals-2017-01,amr_prevalence,amr_prevalence,5,20,Eritrea,tertiary,hospital,,isolates,,2017,2017,Staphylococcus aureus,clindamycin,critically_important,disk_diffusion,CLSI,CLSI 2017 (M100-S25),wound_swab,MDR: nonsusceptibility to at least one agent in ≥3 antimicrobial drug classes.,17.0,,,,,,,disk diffusion (oxacillin disk); D-test for inducible resistance,,,,,mm,,,
Garoy2021-Eritrea-AsmaraHospitals-2017-01,amr_prevalence,amr_prevalence,5,20,Eritrea,tertiary,hospital,,isolates,,2017,2017,Staphylococcus aureus,erythromycin,important,disk_diffusion,CLSI,CLSI 2017 (M100-S25),wound_swab,MDR: nonsusceptibility to at least one agent in ≥3 antimicrobial drug classes.,17.0,,,,,,,disk diffusion (oxacillin disk); D-test for inducible resistance,,,,,mm,,,
Garoy2021-Eritrea-AsmaraHospitals-2017-01,amr_prevalence,amr_prevalence,10,10,Eritrea,tertiary,hospital,,isolates,,2017,2017,Escherichia coli,ampicillin,critically_important,disk_diffusion,CLSI,CLSI 2017 (M100-S25),wound_swab,MDR: nonsusceptibility to at least one agent in ≥3 antimicrobial drug classes.,10.0,,,,,,,,,,,,mm,,,
Garoy2021-Eritrea-AsmaraHospitals-2017-01,amr_prevalence,amr_prevalence,9,10,Eritrea,tertiary,hospital,,isolates,,2017,2017,Escherichia coli,trimethoprim-sulfamethoxazole,critically_important,disk_diffusion,CLSI,CLSI 2017 (M100-S25),wound_swab,MDR: nonsusceptibility to at least one agent in ≥3 antimicrobial drug classes.,10.0,,,,,,,,,,,,mm,,,
Garoy2021-Eritrea-AsmaraHospitals-2017-01,amr_prevalence,amr_prevalence,7,10,Eritrea,tertiary,hospital,,isolates,,2017,2017,Escherichia coli,gentamicin,critically_important,disk_diffusion,CLSI,CLSI 2017 (M100-S25),wound_swab,MDR: nonsusceptibility to at least one agent in ≥3 antimicrobial drug classes.,10.0,,,,,,,,,,,,mm,,,
Garoy2021-Eritrea-AsmaraHospitals-2017-01,amr_prevalence,amr_prevalence,9,10,Eritrea,tertiary,hospital,,isolates,,2017,2017,Escherichia coli,ceftazidime,critically_important,disk_diffusion,CLSI,CLSI 2017 (M100-S25),wound_swab,MDR: nonsusceptibility to at least one agent in ≥3 antimicrobial drug classes.,10.0,,,,,,,,,,,,mm,,,
Garoy2021-Eritrea-AsmaraHospitals-2017-01,amr_prevalence,amr_prevalence,8,10,Eritrea,tertiary,hospital,,isolates,,2017,2017,Escherichia coli,ceftriaxone,critically_important,disk_diffusion,CLSI,CLSI 2017 (M100-S25),wound_swab,MDR: nonsusceptibility to at least one agent in ≥3 antimicrobial drug classes.,10.0,,,,,,,,,,,,mm,,,
Gentilotti2020-Tanzania-Dodoma-2013-2015-1,amr_prevalence,amr_prevalence,34,43,Tanzania,tertiary,hospital,,isolates,,2013,2013,Staphylococcus aureus,oxacillin,highly_important,disk_diffusion,EUCAST,2013/2014,wound_swab,,,,,,,,,oxacillin disc diffusion,,,,,,,,
Gentilotti2020-Tanzania-Dodoma-2013-2015-1,amr_prevalence,amr_prevalence,3,14,Tanzania,tertiary,hospital,,isolates,,2015,2015,Staphylococcus aureus,oxacillin,highly_important,disk_diffusion,EUCAST,2013/2014,wound_swab,,,,,,,,,oxacillin disc diffusion,,,,,,,,
Gentilotti2020-Tanzania-Dodoma-2013-2015-1,amr_prevalence,amr_prevalence,4,4,Tanzania,tertiary,hospital,,isolates,,2013,2013,Klebsiella spp.,multiple_classes,,disk_diffusion,EUCAST,2013/2014,wound_swab,"Resistances to amoxicillin/clavulanate, ceftriaxone (or ceftazidime), and/or gentamycin, and/or ciprofloxacin.",4.0,,,,,,,,,,,,,,,
Gentilotti2020-Tanzania-Dodoma-2013-2015-1,amr_prevalence,amr_prevalence,3,7,Tanzania,tertiary,hospital,,isolates,,2015,2015,Klebsiella spp.,multiple_classes,,disk_diffusion,EUCAST,2013/2014,wound_swab,"Resistances to amoxicillin/clavulanate, ceftriaxone (or ceftazidime), and/or gentamycin, and/or ciprofloxacin.",3.0,,,,,,,,,,,,,,,
Hamudu2025-Tanzania-BMC_SRHH-2024-01,amr_prevalence,amr_prevalence,10,11,Tanzania,tertiary,hospital,,isolates,,2024,2024,Escherichia coli,ampicillin,critically_important,disk_diffusion,CLSI,,wound_swab,Multi drug resistance phenotype reported.,,,,,,,,,,,,,mm,,,
Hamudu2025-Tanzania-BMC_SRHH-2024-01,amr_prevalence,amr_prevalence,4,7,Tanzania,tertiary,hospital,,isolates,,2024,2024,Staphylococcus aureus,ceftriaxone,critically_important,disk_diffusion,CLSI,,wound_swab,Multi drug resistance phenotype reported.,,,,,,,,,,,,,mm,,,
Hamudu2025-Tanzania-BMC_SRHH-2024-01,amr_prevalence,amr_prevalence,1,4,Tanzania,tertiary,hospital,,isolates,,2024,2024,Pseudomonas aeruginosa,ceftazidime,critically_important,disk_diffusion,CLSI,,wound_swab,Multi drug resistance phenotype reported.,,,,,,,,,,,,,mm,,,
Hamudu2025-Tanzania-BMC_SRHH-2024-01,amr_prevalence,amr_prevalence,1,3,Tanzania,tertiary,hospital,,isolates,,2024,2024,Enterococcus faecalis,ampicillin,important,disk_diffusion,CLSI,,wound_swab,Multi drug resistance phenotype reported.,,,,,,,,,,,,,mm,,,
Hope2019-Uganda-Mbarara-2015-01,amr_prevalence,amr_prevalence,20,20,Uganda,tertiary,hospital,,isolates,,2015,2015,Staphylococcus aureus,ampicillin,important,disk_diffusion,CLSI,CLSI 2012,wound_swab,Resistance to three or more antibiotics tested.,18.0,,,,,,,Oxacillin disk diffusion,,,,,mm,,,
Hope2019-Uganda-Mbarara-2015-01,amr_prevalence,amr_prevalence,20,20,Uganda,tertiary,hospital,,isolates,,2015,2015,Staphylococcus aureus,oxacillin,important,disk_diffusion,CLSI,CLSI 2012,wound_swab,Resistance to three or more antibiotics tested.,18.0,,,,,,,Oxacillin disk diffusion,,,,,mm,,,
Hope2019-Uganda-Mbarara-2015-01,amr_prevalence,amr_prevalence,27,27,Uganda,tertiary,hospital,,isolates,,2015,2015,Klebsiella spp.,ampicillin,important,disk_diffusion,CLSI,CLSI 2012,wound_swab,Resistance to three or more antibiotics tested.,27.0,,,,,,,,,,,,mm,,,
Hope2019-Uganda-Mbarara-2015-01,amr_prevalence,amr_prevalence,23,27,Uganda,tertiary,hospital,,isolates,,2015,2015,Klebsiella spp.,ceftriaxone,critically_important,disk_diffusion,CLSI,CLSI 2012,wound_swab,Resistance to three or more antibiotics tested.,27.0,,,,,,,,,,,,mm,,,
Hope2019-Uganda-Mbarara-2015-01,amr_prevalence,amr_prevalence,9,9,Uganda,tertiary,hospital,,isolates,,2015,2015,Escherichia coli,ampicillin,important,disk_diffusion,CLSI,CLSI 2012,wound_swab,Resistance to three or more antibiotics tested.,9.0,,,,,,,,,,,,mm,,,
Hope2019-Uganda-Mbarara-2015-01,amr_prevalence,amr_prevalence,9,9,Uganda,tertiary,hospital,,isolates,,2015,2015,Escherichia coli,ceftriaxone,critically_important,disk_diffusion,CLSI,CLSI 2012,wound_swab,Resistance to three or more antibiotics tested.,9.0,,,,,,,,,,,,mm,,,
Iyamba2014-DRC-Kinshasa-2013-01,amr_prevalence,amr_prevalence,58,74,Democratic Republic of Congo,tertiary,hospital,,isolates,,2013,2013,Staphylococcus aureus,ampicillin,important,disk_diffusion,CLSI,CLSI 2011,wound_swab,Multidrug resistance was observed in MRSA and MR-CNS strains.,,,,,,,,disk diffusion using oxacillin (1 µg) on Mueller Hinton agar with 4% NaCl,,,,,mm,,,
Iyamba2014-DRC-Kinshasa-2013-01,amr_prevalence,amr_prevalence,9,74,Democratic Republic of Congo,tertiary,hospital,,isolates,,2013,2013,Staphylococcus aureus,amoxicillin-clavulanate,critically_important,disk_diffusion,CLSI,CLSI 2011,wound_swab,Multidrug resistance was observed in MRSA and MR-CNS strains.,,,,,,,,disk diffusion using oxacillin (1 µg) on Mueller Hinton agar with 4% NaCl,,,,,mm,,,
Iyamba2014-DRC-Kinshasa-2013-01,amr_prevalence,amr_prevalence,37,74,Democratic Republic of Congo,tertiary,hospital,,isolates,,2013,2013,Staphylococcus aureus,ceftazidime,critically_important,disk_diffusion,CLSI,CLSI 2011,wound_swab,Multidrug resistance was observed in MRSA and MR-CNS strains.,,,,,,,,disk diffusion using oxacillin (1 µg) on Mueller Hinton agar with 4% NaCl,,,,,mm,,,
Iyamba2014-DRC-Kinshasa-2013-01,amr_prevalence,amr_prevalence,30,74,Democratic Republic of Congo,tertiary,hospital,,isolates,,2013,2013,Staphylococcus aureus,cefotaxime,critically_important,disk_diffusion,CLSI,CLSI 2011,wound_swab,Multidrug resistance was observed in MRSA and MR-CNS strains.,,,,,,,,disk diffusion using oxacillin (1 µg) on Mueller Hinton agar with 4% NaCl,,,,,mm,,,
Iyamba2014-DRC-Kinshasa-2013-01,amr_prevalence,amr_prevalence,50,74,Democratic Republic of Congo,tertiary,hospital,,isolates,,2013,2013,Staphylococcus aureus,ciprofloxacin,critically_important,disk_diffusion,CLSI,CLSI 2011,wound_swab,Multidrug resistance was observed in MRSA and MR-CNS strains.,,,,,,,,disk diffusion using oxacillin (1 µg) on Mueller Hinton agar with 4% NaCl,,,,,mm,,,
Iyamba2014-DRC-Kinshasa-2013-01,amr_prevalence,amr_prevalence,52,74,Democratic Republic of Congo,tertiary,hospital,,isolates,,2013,2013,Staphylococcus aureus,clindamycin,critically_important,disk_diffusion,CLSI,CLSI 2011,wound_swab,Multidrug resistance was observed in MRSA and MR-CNS strains.,,,,,,,,disk diffusion using oxacillin (1 µg) on Mueller Hinton agar with 4% NaCl,,,,,mm,,,
Iyamba2014-DRC-Kinshasa-2013-01,amr_prevalence,amr_prevalence,54,74,Democratic Republic of Congo,tertiary,hospital,,isolates,,2013,2013,Staphylococcus aureus,cotrimoxazole,critically_important,disk_diffusion,CLSI,CLSI 2011,wound_swab,Multidrug resistance was observed in MRSA and MR-CNS strains.,,,,,,,,disk diffusion using oxacillin (1 µg) on Mueller Hinton agar with 4% NaCl,,,,,mm,,,
Iyamba2014-DRC-Kinshasa-2013-01,amr_prevalence,amr_prevalence,51,74,Democratic Republic of Congo,tertiary,hospital,,isolates,,2013,2013,Staphylococcus aureus,erythromycin,critically_important,disk_diffusion,CLSI,CLSI 2011,wound_swab,Multidrug resistance was observed in MRSA and MR-CNS strains.,,,,,,,,disk diffusion using oxacillin (1 µg) on Mueller Hinton agar with 4% NaCl,,,,,mm,,,
Iyamba2014-DRC-Kinshasa-2013-01,amr_prevalence,amr_prevalence,0,74,Democratic Republic of Congo,tertiary,hospital,,isolates,,2013,2013,Staphylococcus aureus,imipenem,critically_important,disk_diffusion,CLSI,CLSI 2011,wound_swab,Multidrug resistance was observed in MRSA and MR-CNS strains.,,,,,,,,disk diffusion using oxacillin (1 µg) on Mueller Hinton agar with 4% NaCl,,,,,mm,,,
Iyamba2014-DRC-Kinshasa-2013-01,amr_prevalence,amr_prevalence,11,74,Democratic Republic of Congo,tertiary,hospital,,isolates,,2013,2013,Staphylococcus aureus,vancomycin,critically_important,disk_diffusion,CLSI,CLSI 2011,wound_swab,Multidrug resistance was observed in MRSA and MR-CNS strains.,,,,,,,,disk diffusion using oxacillin (1 µg) on Mueller Hinton agar with 4% NaCl,,,,,mm,,,
Kachipedzu2024-Malawi-QECH-2023-1,amr_prevalence,amr_prevalence,1,1,Malawi,tertiary,hospital,,isolates,,2023,2023,Acinetobacter baumannii,ceftriaxone,critically_important,disk_diffusion,unspecified,,wound_swab,,,,,,,,,,,,,,,,,
Kachipedzu2024-Malawi-QECH-2023-1,amr_prevalence,amr_prevalence,1,1,Malawi,tertiary,hospital,,isolates,,2023,2023,Acinetobacter baumannii,ciprofloxacin,critically_important,disk_diffusion,unspecified,,wound_swab,,,,,,,,,,,,,,,,,
Kachipedzu2024-Malawi-QECH-2023-1,amr_prevalence,amr_prevalence,0,1,Malawi,tertiary,hospital,,isolates,,2023,2023,Acinetobacter baumannii,gentamicin,highly_important,disk_diffusion,unspecified,,wound_swab,,,,,,,,,,,,,,,,,
Kachipedzu2024-Malawi-QECH-2023-1,amr_prevalence,amr_prevalence,1,1,Malawi,tertiary,hospital,,isolates,,2023,2023,Acinetobacter baumannii,cefotaxime,critically_important,disk_diffusion,unspecified,,wound_swab,,,,,,,,,,,,,,,,,
Kachipedzu2024-Malawi-QECH-2023-1,amr_prevalence,amr_prevalence,1,1,Malawi,tertiary,hospital,,isolates,,2023,2023,Acinetobacter baumannii,tigecycline,highly_important,disk_diffusion,unspecified,,wound_swab,,,,,,,,,,,,,,,,,
Kachipedzu2024-Malawi-QECH-2023-1,amr_prevalence,amr_prevalence,1,1,Malawi,tertiary,hospital,,isolates,,2023,2023,Enterobacteriaceae,chloramphenicol,highly_important,disk_diffusion,unspecified,,wound_swab,,,,,,,,,,,,,,,,,
Kachipedzu2024-Malawi-QECH-2023-1,amr_prevalence,amr_prevalence,0,1,Malawi,tertiary,hospital,,isolates,,2023,2023,Enterobacteriaceae,ciprofloxacin,critically_important,disk_diffusion,unspecified,,wound_swab,,,,,,,,,,,,,,,,,
Kachipedzu2024-Malawi-QECH-2023-1,amr_prevalence,amr_prevalence,1,1,Malawi,tertiary,hospital,,isolates,,2023,2023,Enterobacteriaceae,co-trimoxazole,highly_important,disk_diffusion,unspecified,,wound_swab,,,,,,,,,,,,,,,,,
Kachipedzu2024-Malawi-QECH-2023-1,amr_prevalence,amr_prevalence,0,1,Malawi,tertiary,hospital,,isolates,,2023,2023,Enterobacteriaceae,gentamicin,highly_important,disk_diffusion,unspecified,,wound_swab,,,,,,,,,,,,,,,,,
Kachipedzu2024-Malawi-QECH-2023-1,amr_prevalence,amr_prevalence,0,1,Malawi,tertiary,hospital,,isolates,,2023,2023,Enterobacteriaceae,meropenem,critically_important,disk_diffusion,unspecified,,wound_swab,,,,,,,,,,,,,,,,,
Kachipedzu2024-Malawi-QECH-2023-1,amr_prevalence,amr_prevalence,0,1,Malawi,tertiary,hospital,,isolates,,2023,2023,Enterobacteriaceae,amikacin,highly_important,disk_diffusion,unspecified,,wound_swab,,,,,,,,,,,,,,,,,
Kachipedzu2024-Malawi-QECH-2023-1,amr_prevalence,amr_prevalence,0,1,Malawi,tertiary,hospital,,isolates,,2023,2023,Enterobacteriaceae,tigecycline,highly_important,disk_diffusion,unspecified,,wound_swab,,,,,,,,,,,,,,,,,
Kachipedzu2024-Malawi-QECH-2023-1,amr_prevalence,amr_prevalence,3,3,Malawi,tertiary,hospital,,isolates,,2023,2023,Staphylococcus aureus,clindamycin,highly_important,disk_diffusion,unspecified,,wound_swab,,,,,,,,,,,,,,,,,
Kachipedzu2024-Malawi-QECH-2023-1,amr_prevalence,amr_prevalence,3,3,Malawi,tertiary,hospital,,isolates,,2023,2023,Staphylococcus aureus,erythromycin,highly_important,disk_diffusion,unspecified,,wound_swab,,,,,,,,,,,,,,,,,
Kachipedzu2024-Malawi-QECH-2023-1,amr_prevalence,amr_prevalence,3,3,Malawi,tertiary,hospital,,isolates,,2023,2023,Staphylococcus aureus,gentamicin,highly_important,disk_diffusion,unspecified,,wound_swab,,,,,,,,,,,,,,,,,
Kachipedzu2024-Malawi-QECH-2023-1,amr_prevalence,amr_prevalence,3,3,Malawi,tertiary,hospital,,isolates,,2023,2023,Staphylococcus aureus,cefoxitin,highly_important,disk_diffusion,unspecified,,wound_swab,,,,,,,,,Cefoxitin screen suggests MRSA.,,,,,,,,
Akoachere2014-Cameroon-Buea-201010201103-01,amr_prevalence,amr_prevalence,0,48,Cameroon,mixed,hospital,,isolates,,2010,2011,Staphylococcus aureus,ofloxacin,critically_important,disk_diffusion,CLSI,CLSI 2009,wound_swab,Resistance to at least two drugs (excluding oxacillin),,,,,,,,,,,,,mm,,,
Akoachere2014-Cameroon-Buea-201010201103-01,amr_prevalence,amr_prevalence,48,48,Cameroon,mixed,hospital,,isolates,,2010,2011,Staphylococcus aureus,oxacillin,critically_important,disk_diffusion,CLSI,CLSI 2009,wound_swab,Resistance to at least two drugs (excluding oxacillin),,,,,,,,,,,,,mm,,,
Akoachere2014-Cameroon-Buea-201010201103-01,amr_prevalence,amr_prevalence,6,48,Cameroon,mixed,hospital,,isolates,,2010,2011,Staphylococcus aureus,gentamicin,critically_important,disk_diffusion,CLSI,CLSI 2009,wound_swab,Resistance to at least two drugs (excluding oxacillin),,,,,,,,,,,,,mm,,,
Akoachere2014-Cameroon-Buea-201010201103-01,amr_prevalence,amr_prevalence,0,39,Cameroon,mixed,hospital,,isolates,,2010,2011,Pseudomonas aeruginosa,ofloxacin,critically_important,disk_diffusion,CLSI,CLSI 2009,wound_swab,Resistance to at least two drugs (excluding oxacillin),,,,,,,,,,,,,mm,,,
Akoachere2014-Cameroon-Buea-201010201103-01,amr_prevalence,amr_prevalence,10,39,Cameroon,mixed,hospital,,isolates,,2010,2011,Pseudomonas aeruginosa,gentamicin,critically_important,disk_diffusion,CLSI,CLSI 2009,wound_swab,Resistance to at least two drugs (excluding oxacillin),,,,,,,,,,,,,mm,,,
Akoachere2014-Cameroon-Buea-201010201103-01,amr_prevalence,amr_prevalence,0,22,Cameroon,mixed,hospital,,isolates,,2010,2011,Klebsiella pneumoniae,ofloxacin,critically_important,disk_diffusion,CLSI,CLSI 2009,wound_swab,Resistance to at least two drugs (excluding oxacillin),,,,,,,,,,,,,mm,,,
Kumburu2017-Tanzania-KCMC-2013-2015-01,amr_prevalence,amr_prevalence,21,28,Tanzania,tertiary,hospital,,isolates,,2013,2015,Proteus spp.,ampicillin,important,disk_diffusion,CLSI,CLSI 2013,wound_swab,,,,,,,,,,,,,,mm,,,
Kumburu2017-Tanzania-KCMC-2013-2015-01,amr_prevalence,amr_prevalence,23,28,Tanzania,tertiary,hospital,,isolates,,2013,2015,Proteus spp.,cefazolin,important,disk_diffusion,CLSI,CLSI 2013,wound_swab,,,,,,,,,,,,,,mm,,,
Kumburu2017-Tanzania-KCMC-2013-2015-01,amr_prevalence,amr_prevalence,24,26,Tanzania,tertiary,hospital,,isolates,,2013,2015,Klebsiella spp.,ampicillin,important,disk_diffusion,CLSI,CLSI 2013,wound_swab,,,,,,,,,,,,,,mm,,,
Kumburu2017-Tanzania-KCMC-2013-2015-01,amr_prevalence,amr_prevalence,13,19,Tanzania,tertiary,hospital,,isolates,,2013,2015,Escherichia coli,ampicillin,important,disk_diffusion,CLSI,CLSI 2013,wound_swab,,,,,,,,,,,,,,mm,,,
Kumburu2017-Tanzania-KCMC-2013-2015-01,amr_prevalence,amr_prevalence,22,22,Tanzania,tertiary,hospital,,isolates,,2013,2015,Staphylococcus aureus,penicillin,important,disk_diffusion,CLSI,CLSI 2013,wound_swab,,,,,,,,,Cefoxitin disk diffusion,,,,,mm,,,
Kumburu2017-Tanzania-KCMC-2013-2015-01,amr_prevalence,amr_prevalence,6,22,Tanzania,tertiary,hospital,,isolates,,2013,2015,Staphylococcus aureus,cefoxitin,important,disk_diffusion,CLSI,CLSI 2013,wound_swab,,,,,,,,,Cefoxitin disk diffusion,,,,,mm,,,
Jung2023-Uganda-Mulago-2021Q4_2022Q1-01,amr_prevalence,amr_prevalence,43,45,Uganda,tertiary,hospital,,isolates,,2021,2022,Escherichia coli,ceftriaxone,critically_important,disk_diffusion,CLSI,CLSI 2020,wound_swab,,,,disk diffusion (cephalosporin/clavulanic acid combination),,,,,,,,,,mm,,,
Jung2023-Uganda-Mulago-2021Q4_2022Q1-01,amr_prevalence,amr_prevalence,22,40,Uganda,tertiary,hospital,,isolates,,2021,2022,Escherichia coli,gentamicin,critically_important,disk_diffusion,CLSI,CLSI 2020,wound_swab,,,,disk diffusion (cephalosporin/clavulanic acid combination),,,,,,,,,,mm,,,
Jung2023-Uganda-Mulago-2021Q4_2022Q1-01,amr_prevalence,amr_prevalence,32,39,Uganda,tertiary,hospital,,isolates,,2021,2022,Acinetobacter spp.,gentamicin,critically_important,disk_diffusion,CLSI,CLSI 2020,wound_swab,,,,,,,,,,,,,,mm,,,
Jung2023-Uganda-Mulago-2021Q4_2022Q1-01,amr_prevalence,amr_prevalence,30,32,Uganda,tertiary,hospital,,isolates,,2021,2022,Klebsiella spp.,ceftriaxone,critically_important,disk_diffusion,CLSI,CLSI 2020,wound_swab,,,,,,,,,,,,,,mm,,,
Jung2023-Uganda-Mulago-2021Q4_2022Q1-01,amr_prevalence,amr_prevalence,11,24,Uganda,tertiary,hospital,,isolates,,2021,2022,Pseudomonas aeruginosa,gentamicin,critically_important,disk_diffusion,CLSI,CLSI 2020,wound_swab,,,,,,,,,,,,,,mm,,,
Jung2023-Uganda-Mulago-2021Q4_2022Q1-01,amr_prevalence,amr_prevalence,17,20,Uganda,tertiary,hospital,,isolates,,2021,2022,Enterococcus spp.,vancomycin,critically_important,disk_diffusion,CLSI,CLSI 2020,wound_swab,,,,,,,,,,,,,,mm,,,
Jung2023-Uganda-Mulago-2021Q4_2022Q1-01,amr_prevalence,amr_prevalence,4,19,Uganda,tertiary,hospital,,isolates,,2021,2022,Staphylococcus aureus,methicillin,critically_important,disk_diffusion,CLSI,CLSI 2020,wound_swab,,,,,,,,,,,,,,mm,,,
Manyahi2014-Tanzania-Muhimbili-2011-2012-1,amr_prevalence,amr_prevalence,13,13,Tanzania,tertiary,hospital,,isolates,,2011,2012,Escherichia coli,ampicillin,critically_important,disk_diffusion,CLSI,CLSI 2010,wound_swab,MDR defined as acquired non-susceptibility to at least one agent in three or more antimicrobial categories.,13.0,,Double disc approximation method,12.0,,,,,,,,,mm,,,
Manyahi2014-Tanzania-Muhimbili-2011-2012-1,amr_prevalence,amr_prevalence,12,13,Tanzania,tertiary,hospital,,isolates,,2011,2012,Escherichia coli,amoxicillin-clavulanate,critically_important,disk_diffusion,CLSI,CLSI 2010,wound_swab,MDR defined as acquired non-susceptibility to at least one agent in three or more antimicrobial categories.,13.0,,Double disc approximation method,12.0,,,,,,,,,mm,,,
Manyahi2014-Tanzania-Muhimbili-2011-2012-1,amr_prevalence,amr_prevalence,12,13,Tanzania,tertiary,hospital,,isolates,,2011,2012,Escherichia coli,ceftriaxone,critically_important,disk_diffusion,CLSI,CLSI 2010,wound_swab,MDR defined as acquired non-susceptibility to at least one agent in three or more antimicrobial categories.,13.0,,Double disc approximation method,12.0,,,,,,,,,mm,,,
Manyahi2014-Tanzania-Muhimbili-2011-2012-1,amr_prevalence,amr_prevalence,15,18,Tanzania,tertiary,hospital,,isolates,,2011,2012,Staphylococcus aureus,penicillin,critically_important,disk_diffusion,CLSI,CLSI 2010,wound_swab,MDR defined as acquired non-susceptibility to at least one agent in three or more antimicrobial categories.,8.0,,,,,,,Cefoxitin disc diffusion (zone ≤21 mm),,,,,mm,,,
Manyahi2014-Tanzania-Muhimbili-2011-2012-1,amr_prevalence,amr_prevalence,16,16,Tanzania,tertiary,hospital,,isolates,,2011,2012,Klebsiella pneumoniae,ampicillin,critically_important,disk_diffusion,CLSI,CLSI 2010,wound_swab,MDR defined as acquired non-susceptibility to at least one agent in three or more antimicrobial categories.,14.0,,Double disc approximation method,11.0,,,,,,,,,mm,,,
Mengesha2014-Ethiopia-Ayder-2012-1,amr_prevalence,amr_prevalence,4,40,Ethiopia,tertiary,hospital,,isolates,,2012,2012,Staphylococcus aureus,gentamicin,critically_important,disk_diffusion,CLSI,CLSI 2011,wound_swab,,,,,,,,,,,,,,mm,,,
Mengesha2014-Ethiopia-Ayder-2012-1,amr_prevalence,amr_prevalence,0,40,Ethiopia,tertiary,hospital,,isolates,,2012,2012,Staphylococcus aureus,vancomycin,critically_important,disk_diffusion,CLSI,CLSI 2011,wound_swab,,,,,,,,,,,,,,mm,,,
Mengesha2014-Ethiopia-Ayder-2012-1,amr_prevalence,amr_prevalence,8,29,Ethiopia,tertiary,hospital,,isolates,,2012,2012,Klebsiella spp.,gentamicin,critically_important,disk_diffusion,CLSI,CLSI 2011,wound_swab,,,,,,,,,,,,,,mm,,,
Mengesha2014-Ethiopia-Ayder-2012-1,amr_prevalence,amr_prevalence,0,11,Ethiopia,tertiary,hospital,,isolates,,2012,2012,Pseudomonas aeruginosa,gentamicin,critically_important,disk_diffusion,CLSI,CLSI 2011,wound_swab,,,,,,,,,,,,,,mm,,,
Mengesha2014-Ethiopia-Ayder-2012-1,amr_prevalence,amr_prevalence,0,18,Ethiopia,tertiary,hospital,,isolates,,2012,2012,Coagulase-negative staphylococci,vancomycin,critically_important,disk_diffusion,CLSI,CLSI 2011,wound_swab,,,,,,,,,,,,,,mm,,,
Mengesha2014-Ethiopia-Ayder-2012-1,amr_prevalence,amr_prevalence,11,65,Ethiopia,tertiary,hospital,,isolates,,2012,2012,Gram-negative bacteria (aggregate),gentamicin,critically_important,disk_diffusion,CLSI,CLSI 2011,wound_swab,,,,,,,,,,,,,,mm,,,
Mengesha2014-Ethiopia-Ayder-2012-1,amr_prevalence,amr_prevalence,0,58,Ethiopia,tertiary,hospital,,isolates,,2012,2012,Gram-positive bacteria (aggregate),vancomycin,critically_important,disk_diffusion,CLSI,CLSI 2011,wound_swab,,,,,,,,,,,,,,mm,,,
Misha2021-Ethiopia-JimmaMedicalCenter-2019-01,amr_prevalence,amr_prevalence,3,5,Ethiopia,tertiary,hospital,,isolates,,2019,2019,Staphylococcus aureus,penicillin,important,disk_diffusion,CLSI,CLSI 2018,wound_swab,Multi-drug resistance (MDR) to commonly used antibiotics was identified.,,,,,,,,,,,,,mm,,,
Misha2021-Ethiopia-JimmaMedicalCenter-2019-01,amr_prevalence,amr_prevalence,4,5,Ethiopia,tertiary,hospital,,isolates,,2019,2019,Staphylococcus aureus,erythromycin,important,disk_diffusion,CLSI,CLSI 2018,wound_swab,Multi-drug resistance (MDR) to commonly used antibiotics was identified.,,,,,,,,,,,,,mm,,,
Misha2021-Ethiopia-JimmaMedicalCenter-2019-01,amr_prevalence,amr_prevalence,4,5,Ethiopia,tertiary,hospital,,isolates,,2019,2019,Staphylococcus aureus,clindamycin,important,disk_diffusion,CLSI,CLSI 2018,wound_swab,Multi-drug resistance (MDR) to commonly used antibiotics was identified.,,,,,,,,,,,,,mm,,,
Misha2021-Ethiopia-JimmaMedicalCenter-2019-01,amr_prevalence,amr_prevalence,0,9,Ethiopia,tertiary,hospital,,isolates,,2019,2019,Escherichia coli,meropenem,critically_important,disk_diffusion,CLSI,CLSI 2018,wound_swab,Multi-drug resistance (MDR) to commonly used antibiotics was identified.,,,,,,,,,,,,,mm,,,
Misha2021-Ethiopia-JimmaMedicalCenter-2019-01,amr_prevalence,amr_prevalence,8,8,Ethiopia,tertiary,hospital,,isolates,,2019,2019,Pseudomonas aeruginosa,ceftriaxone,critically_important,disk_diffusion,CLSI,CLSI 2018,wound_swab,Multi-drug resistance (MDR) to commonly used antibiotics was identified.,,,,,,,,,,,,,mm,,,
Misha2021-Ethiopia-JimmaMedicalCenter-2019-01,amr_prevalence,amr_prevalence,6,6,Ethiopia,tertiary,hospital,,isolates,,2019,2019,Proteus spp.,ceftriaxone,critically_important,disk_diffusion,CLSI,CLSI 2018,wound_swab,Multi-drug resistance (MDR) to commonly used antibiotics was identified.,,,,,,,,,,,,,mm,,,
DeNardo2016-Tanzania-Dodoma-2013-1,amr_prevalence,amr_prevalence,34,43,Tanzania,tertiary,hospital,,isolates,,2013,2013,Staphylococcus aureus,oxacillin,critically_important,disk_diffusion,EUCAST,"Version 5.0, 2015",wound_swab,,,,,,,,,diffusion method with oxacillin disc,,,,,,,,
Odoko2024-Ethiopia-SodoHospitals-2022-01,amr_prevalence,amr_prevalence,26,29,Ethiopia,tertiary,hospital,,isolates,,2022,2022,Escherichia coli,cefepime,critically_important,disk_diffusion,CLSI,CLSI 2021,wound_swab,MDR: resistant to at least one agent in three or more antimicrobial categories.,14.0,11,double-disc synergy test,25.0,modified Hodge test,4.0,"NDM (2), KPC (1)",,,,,,mm,,,
Odoko2024-Ethiopia-SodoHospitals-2022-01,amr_prevalence,amr_prevalence,14,14,Ethiopia,tertiary,hospital,,isolates,,2022,2022,Klebsiella pneumoniae,cefepime,critically_important,disk_diffusion,CLSI,CLSI 2021,wound_swab,MDR: resistant to at least one agent in three or more antimicrobial categories.,3.0,10,double-disc synergy test,7.0,modified Hodge test,7.0,,,,,,,mm,,,
Odoko2024-Ethiopia-SodoHospitals-2022-01,amr_prevalence,amr_prevalence,4,29,Ethiopia,tertiary,hospital,,isolates,,2022,2022,Escherichia coli,meropenem,critically_important,disk_diffusion,CLSI,CLSI 2021,wound_swab,MDR: resistant to at least one agent in three or more antimicrobial categories.,14.0,11,double-disc synergy test,25.0,modified Hodge test,4.0,"NDM (2), KPC (1)",,,,,,mm,,,
Odoko2024-Ethiopia-SodoHospitals-2022-01,amr_prevalence,amr_prevalence,9,14,Ethiopia,tertiary,hospital,,isolates,,2022,2022,Klebsiella pneumoniae,meropenem,critically_important,disk_diffusion,CLSI,CLSI 2021,wound_swab,MDR: resistant to at least one agent in three or more antimicrobial categories.,3.0,10,double-disc synergy test,7.0,modified Hodge test,7.0,,,,,,,mm,,,
Ojulong2009-Uganda-Mulago-2007-01,amr_prevalence,amr_prevalence,12,17,Uganda,tertiary,hospital,,isolates,,2007,2007,Staphylococcus aureus,ciprofloxacin,critically_important,disk_diffusion,CLSI,CLSI 2003,wound_swab,,,,,,,,,PCR,,,,,mm,,,
Ojulong2009-Uganda-Mulago-2007-01,amr_prevalence,amr_prevalence,0,17,Uganda,tertiary,hospital,,isolates,,2007,2007,Staphylococcus aureus,vancomycin,critically_important,disk_diffusion,CLSI,CLSI 2003,wound_swab,,,,,,,,,PCR,,,,,mm,,,
Ojulong2009-Uganda-Mulago-2007-01,amr_prevalence,amr_prevalence,0,17,Uganda,tertiary,hospital,,isolates,,2007,2007,Staphylococcus aureus,clindamycin,critically_important,disk_diffusion,CLSI,CLSI 2003,wound_swab,Inducible clindamycin resistance detected by D-test; 82.4% positive.,,,,,,,,PCR,erm gene (inducible resistance),,,,mm,,,
Ojulong2009-Uganda-Mulago-2007-01,amr_prevalence,amr_prevalence,10,17,Uganda,tertiary,hospital,,isolates,,2007,2007,Staphylococcus aureus,gentamicin,critically_important,disk_diffusion,CLSI,CLSI 2003,wound_swab,,,,,,,,,PCR,,,,,mm,,,
Ojulong2009-Uganda-Mulago-2007-01,amr_prevalence,amr_prevalence,15,17,Uganda,tertiary,hospital,,isolates,,2007,2007,Staphylococcus aureus,co-trimoxazole,highly_important,disk_diffusion,CLSI,CLSI 2003,wound_swab,,,,,,,,,PCR,,,,,mm,,,
Ojulong2009-Uganda-Mulago-2007-01,amr_prevalence,amr_prevalence,15,17,Uganda,tertiary,hospital,,isolates,,2007,2007,Staphylococcus aureus,chloramphenicol,highly_important,disk_diffusion,CLSI,CLSI 2003,wound_swab,,,,,,,,,PCR,,,,,mm,,,
Ojulong2009-Uganda-Mulago-2007-01,amr_prevalence,amr_prevalence,15,17,Uganda,tertiary,hospital,,isolates,,2007,2007,Staphylococcus aureus,erythromycin,critically_important,disk_diffusion,CLSI,CLSI 2003,wound_swab,,,,,,,,,PCR,,,,,mm,,,
Ojulong2009-Uganda-Mulago-2007-01,amr_prevalence,amr_prevalence,17,54,Uganda,tertiary,hospital,,isolates,,2007,2007,Staphylococcus aureus,oxacillin,critically_important,"oxacillin agar screen, PCR for mecA",CLSI,NCCLS 2003,wound_swab,,,,,,,,,PCR for mecA gene,mecA,,,,,,,
Scherbaum2014-Gabon-Lambarene-2009-01,amr_prevalence,amr_prevalence,0,14,Gabon,tertiary,hospital,,isolates,,2009,2009,Staphylococcus aureus,cloxacillin,important,MIC_broth,CLSI,CLSI 2007,wound_swab,,,,,,,,,PBP2a-agglutination test for cefoxitin-resistant S. aureus,,,,,,,,
Scherbaum2014-Gabon-Lambarene-2009-01,amr_prevalence,amr_prevalence,13,14,Gabon,tertiary,hospital,,isolates,,2009,2009,Escherichia coli,ampicillin,important,MIC_broth,CLSI,CLSI 2007,urine,ESBL production confirmed by double-disks method.,5.0,,double-disks method,5.0,,,,,,,,,,,,
Scherbaum2014-Gabon-Lambarene-2009-01,amr_prevalence,amr_prevalence,5,14,Gabon,tertiary,hospital,,isolates,,2009,2009,Escherichia coli,ceftriaxone,critically_important,MIC_broth,CLSI,CLSI 2007,urine,ESBL production confirmed by double-disks method.,5.0,,double-disks method,5.0,,,,,,,,,,,,
Scherbaum2014-Gabon-Lambarene-2009-01,amr_prevalence,amr_prevalence,3,6,Gabon,tertiary,hospital,,isolates,,2009,2009,Klebsiella pneumoniae,ceftriaxone,critically_important,MIC_broth,CLSI,CLSI 2007,urine,ESBL production confirmed by double-disks method.,3.0,,double-disks method,3.0,,,,,,,,,,,,
Velin2021-Rwanda-KireheDistrictHospital-2019_2020-01,amr_prevalence,amr_prevalence,3,3,Rwanda,secondary,hospital,,isolates,,2019,2020,Escherichia coli,ceftriaxone,critically_important,VITEK2,study_defined,,wound_swab,,,,,,,,,,,,,,,,,
Velin2021-Rwanda-KireheDistrictHospital-2019_2020-01,amr_prevalence,amr_prevalence,8,8,Rwanda,secondary,hospital,,isolates,,2019,2020,Klebsiella pneumoniae,ceftriaxone,critically_important,VITEK2,study_defined,,wound_swab,,,,,,,,,,,,,,,,,
Velin2021-Rwanda-KireheDistrictHospital-2019_2020-01,amr_prevalence,amr_prevalence,7,8,Rwanda,secondary,hospital,,isolates,,2019,2020,Proteus spp.,ceftriaxone,critically_important,VITEK2,study_defined,,wound_swab,,,,,,,,,,,,,,,,,
Velin2021-Rwanda-KireheDistrictHospital-2019_2020-01,amr_prevalence,amr_prevalence,8,8,Rwanda,secondary,hospital,,isolates,,2019,2020,Enterobacter cloacae complex,ceftriaxone,critically_important,VITEK2,study_defined,,wound_swab,,,,,,,,,,,,,,,,,
Velin2021-Rwanda-KireheDistrictHospital-2019_2020-01,amr_prevalence,amr_prevalence,9,9,Rwanda,secondary,hospital,,isolates,,2019,2020,Acinetobacter baumannii complex,ceftriaxone,critically_important,VITEK2,study_defined,,wound_swab,,,,,,,,,,,,,,,,,
Velin2021-Rwanda-KireheDistrictHospital-2019_2020-01,amr_prevalence,amr_prevalence,2,2,Rwanda,secondary,hospital,,isolates,,2019,2020,Staphylococcus aureus,cefoxitin,critically_important,VITEK2,study_defined,,wound_swab,MRSA defined as resistance to cefoxitin.,,,,,,,,cefoxitin resistance by VITEK2,,,,,,,,
Wekesa2020-Uganda-MulagoHospital-201711201804-01,amr_prevalence,amr_prevalence,43,44,Uganda,tertiary,hospital,,isolates,,2017,2018,Klebsiella species,ceftriaxone,critically_important,disk_diffusion,CLSI,CLSI 2017,wound_swab,,,,disc diffusion with ceftazidime/clavulanate,,phenotypic (carbapenem resistance),15.0,,,,,,,mm,,,
Wekesa2020-Uganda-MulagoHospital-201711201804-01,amr_prevalence,amr_prevalence,40,44,Uganda,tertiary,hospital,,isolates,,2017,2018,Klebsiella species,ceftazidime,critically_important,disk_diffusion,CLSI,CLSI 2017,wound_swab,,,,disc diffusion with ceftazidime/clavulanate,19.0,phenotypic (carbapenem resistance),15.0,,,,,,,mm,,,
Wekesa2020-Uganda-MulagoHospital-201711201804-01,amr_prevalence,amr_prevalence,11,11,Uganda,tertiary,hospital,,isolates,,2017,2018,Escherichia coli,ceftriaxone,critically_important,disk_diffusion,CLSI,CLSI 2017,wound_swab,,,,disc diffusion with ceftazidime/clavulanate,,,0.0,,,,,,,mm,,,
Wekesa2020-Uganda-MulagoHospital-201711201804-01,amr_prevalence,amr_prevalence,11,11,Uganda,tertiary,hospital,,isolates,,2017,2018,Escherichia coli,ceftazidime,critically_important,disk_diffusion,CLSI,CLSI 2017,wound_swab,,,,disc diffusion with ceftazidime/clavulanate,10.0,,0.0,,,,,,,mm,,,
Wekesa2020-Uganda-MulagoHospital-201711201804-01,amr_prevalence,amr_prevalence,31,34,Uganda,tertiary,hospital,,isolates,,2017,2018,Staphylococcus aureus,methicillin,critically_important,PCR (mecA gene),study_defined,,wound_swab,,,,,,,,,PCR for mecA gene,mecA,,,,,,,
Worku2024-Ethiopia-Multicenter-2020-2021-1,amr_prevalence,amr_prevalence,41,43,Ethiopia,tertiary,hospital,,isolates,,2020,2021,Acinetobacter baumannii,ceftriaxone,critically_important,disk_diffusion,CLSI,CLSI 2021,wound_swab,,,,Combination Disk Test (CDT),40.0,PCR and sequencing,,"blaOXA, blaNDM",,"blaCTX−M, blaTEM, blaOXA, blaNDM",,,,mm,,,
Worku2024-Ethiopia-Multicenter-2020-2021-1,amr_prevalence,amr_prevalence,41,43,Ethiopia,tertiary,hospital,,isolates,,2020,2021,Acinetobacter baumannii,ceftazidime,critically_important,disk_diffusion,CLSI,CLSI 2021,wound_swab,,,,Combination Disk Test (CDT),,,,,,,,,,mm,,,
Worku2024-Ethiopia-Multicenter-2020-2021-1,amr_prevalence,amr_prevalence,37,43,Ethiopia,tertiary,hospital,,isolates,,2020,2021,Acinetobacter baumannii,imipenem,critically_important,disk_diffusion,CLSI,CLSI 2021,wound_swab,,,,,,PCR and sequencing,37.0,"blaOXA, blaNDM",,"blaOXA, blaNDM",,,,mm,,,
Worku2023-Ethiopia-Multicentre-2020-2021-1,amr_prevalence,amr_prevalence,138,153,Ethiopia,tertiary,hospital,,isolates,,2020,2021,Staphylococcus aureus,penicillin,important,disk_diffusion,CLSI,CLSI 2021,wound_swab,Resistance to at least one drug in three or more categories.,153.0,,,,,,,Cefoxitin disk as surrogate marker,,,,,mm,,,
Worku2023-Ethiopia-Multicentre-2020-2021-1,amr_prevalence,amr_prevalence,117,153,Ethiopia,tertiary,hospital,,isolates,,2020,2021,Staphylococcus aureus,ampicillin,important,disk_diffusion,CLSI,CLSI 2021,wound_swab,Resistance to at least one drug in three or more categories.,153.0,,,,,,,Cefoxitin disk as surrogate marker,,,,,mm,,,
Worku2023-Ethiopia-Multicentre-2020-2021-1,amr_prevalence,amr_prevalence,0,153,Ethiopia,tertiary,hospital,,isolates,,2020,2021,Staphylococcus aureus,vancomycin,critically_important,disk_diffusion,CLSI,CLSI 2021,wound_swab,Resistance to at least one drug in three or more categories.,153.0,,,,,,,Cefoxitin disk as surrogate marker,,,,,mm,,,
Worku2023-Ethiopia-Multicentre-2020-2021-1,amr_prevalence,amr_prevalence,96,102,Ethiopia,tertiary,hospital,,isolates,,2020,2021,Escherichia coli,ampicillin,important,disk_diffusion,CLSI,CLSI 2021,wound_swab,Resistance to at least one drug in three or more categories.,98.0,,,,,,,,,,,,mm,,,
Worku2023-Ethiopia-Multicentre-2020-2021-1,amr_prevalence,amr_prevalence,101,102,Ethiopia,tertiary,hospital,,isolates,,2020,2021,Escherichia coli,ceftriaxone,critically_important,disk_diffusion,CLSI,CLSI 2021,wound_swab,Resistance to at least one drug in three or more categories.,98.0,,,,,,,,,,,,mm,,,
Worku2023-Ethiopia-Multicentre-2020-2021-1,amr_prevalence,amr_prevalence,12,102,Ethiopia,tertiary,hospital,,isolates,,2020,2021,Escherichia coli,imipenem,critically_important,disk_diffusion,CLSI,CLSI 2021,wound_swab,Resistance to at least one drug in three or more categories.,98.0,,,,,,,,,,,,mm,,,
Worku2023-Ethiopia-FourHospitals-2020-2021-1,amr_prevalence,amr_prevalence,40,163,Ethiopia,tertiary,hospital,,isolates,,2020,2021,Staphylococcus aureus,cefoxitin,critically_important,disk_diffusion,CLSI,CLSI 2021,wound_swab,,,,,,,,,Cefoxitin disk diffusion and mecA PCR,"mecA, femA, vanA, vanB",µg/mL,,8,mm,,,
Worku2023-Ethiopia-FourHospitals-2020-2021-1,amr_prevalence,amr_prevalence,1,40,Ethiopia,tertiary,hospital,,isolates,,2020,2021,Staphylococcus aureus,vancomycin,critically_important,MIC_broth,CLSI,CLSI 2021,wound_swab,,,,,,,,,,"vanA, vanB",µg/mL,,8,,,,
